Navigation Links
Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment

OXFORD, England, January 7 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy and critical care, today announced that following successful clinical results achieved in 2008 with its ToleroMune(R) anti-allergy technology, the company has now completed patient recruitment for a further phase II clinical trial in cat allergy. The study, which is underway in Canada, has recruited 120 patients with confirmed cat allergies, and all the participants have completed screening and initial dosing with none experiencing any significant adverse events or safety issues. Circassia anticipates completing patient dosing in the next three months, with follow-up post-treatment challenge visits being completed by the end of April 2009.

The double-blind, randomized, placebo-controlled study is comparing several different ToleroMune treatment regimens, each with standardised doses administered over several weeks. This is in sharp contrast to most current allergy immunotherapies, which can require carefully titrated dosing over many months and even years. As part of the ongoing study, each patient is exposed to cat allergens in a controlled environmental exposure chamber both before and after receiving the study treatment. During these "challenges" the volunteers will monitor and record their allergic rhinitis symptoms to allow investigators to assess the effect of the ToleroMune treatment.

"We are delighted that this trial is making such rapid progress as it should define the optimal treatment approach for our ToleroMune cat-allergy therapy as it moves towards phase III testing," said Steve Harris, Circassia's CEO. "We are commited to introducing our ToleroMune treatment for cat allergy as quickly as possible because, despite its prevalence, the condition is poorly served by existing therapies due to their aggressive side-effect profile. ToleroMune offers allergists and their patients significant potential benefits. In particular, ToleroMune should greatly simplify and shorten allergy therapy, while minimizing the risk of the serious and even life-threatening adverse reactions that are associated with current desensitization treatments."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the fields of allergy and critical care. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Circassia's anti-allergy products offer potential important clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition.

Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. In addition to ToleroMune's potential therapeutic benefits, its state-of-the-art manufacturing processes fit with changes in the regulatory environment in Europe where authorities are increasingly treating allergen immunotherapies in the same manner as pharmaceuticals, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent products. Circassia is also developing ToleroTrans organ anti-rejection technology, which uses a similar approach to ToleroMune to down-regulate immune responses in transplant patients, and ToleroCare therapy which is designed to dramatically improve patient recovery following a range of high-risk surgeries.

For more information please visit

SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
2. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
(Date:11/25/2015)... November 25, 2015 Kitov Pharma ... (TASE: KTOV), a biopharmaceutical company focused on the development ... clinical conditions, today announced the closing of its previously ... ( ADSs ), each representing 20 ordinary shares of ... ADSs. The ADSs and warrants were issued in a ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a ... component is distributed nationally, through a vast social media strategy and across a ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with ... the 2016 Building Better Radiology Marketing Programs meeting will showcase some ... March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
Breaking Medicine News(10 mins):